Zepzelca To Help Diversify Jazz Pharma's Portfolio, Revenue Base

Included In Small-Cell Lung Cancer Guidelines In US For Second-Line Use

15 Jul 2020

• By John Davis

Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.

The addition of Jazz Pharmaceuticals plc’s new anticancer, Zepzelca (lurbinectedin, licensed from PharmaMar, S.A. for the US), to the National Comprehensive Cancer Network’s clinical practice guidelines for small cell lung cancer should help the company’s first solid-tumor anticancer product gain traction in the marketplace, following its approval in the US last month.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.